Broken String Biosciences, a leader in advancing gene editing safety, announced the appointment of new leadership to drive the commercialization of its INDUCE-seq platform, now available to cell and gene therapy developers worldwide.
Health Technology Insights: Health Technology Insights: Latest News And Innovations – Roundup 4 November 2025
To drive the company’s commercial expansion, Terry Pizzie has been appointed as CEO, bringing extensive experience from leading and scaling global life science businesses. Mr. Pizzie has previously held leadership positions, including CEO of Horizon Discovery and Astrea Bioseparations, where he guided both companies through successful growth and exits, as well as senior roles at Pacific Biosciences, GE Healthcare, Applied Biosystems, and Genetix. His appointment marks a significant milestone as Broken String transitions from a pioneering technology developer to a fully commercial organization.
The company’s next stage of growth is focused on scaling access to INDUCE-seq, a proprietary platform that directly maps DNA double-strand breaks to measure and quantify both on- and off-target editing events from any gene editing therapeutic in any cell type. INDUCE-seq is a universal, unbiased solution for mapping genome integrity and was developed to provide a faster and more reliable way to quantify such events, which is critical in evaluating the predicted impact of any gene editing therapy.
Health Technology Insights: Freenome Names Rob Guigley CCO as Exact Sciences Deal Clears
Co-founder and former CEO, Felix Dobbs, will continue to lead company operations and technology development as Chief Operations Officer. Gabe Longoria joins as Chief Commercial Officer, his significant track record of commercial leadership in Cell & Gene Therapy tools adding further depth to the company’s commercial expertise. Co-founder Professor Simon Reed continues in his role as Chief Scientific Officer.
“Terry’s proven track record in building commercially successful life science businesses makes him the ideal leader to guide Broken String through its next phase,” said Felix Dobbs. “Under his leadership, and with Gabe’s commercial acumen, we are now well positioned to make INDUCE-seq the gold standard for gene editing off-target assessment, a crucial step in the delivery of safe gene editing therapies to patients.’’
“Gene editing technologies such as CRISPR and base editing are already transforming what’s possible in medicine,” said Terry Pizzie. “INDUCE-seq gives developers a powerful new way to rapidly and confidently evaluate both the efficacy of on-target editing and the potential impact of off-target effects, helping them design more precise, safer therapies and to advance promising therapies much faster. This is an exciting moment for the company and the industry, and I’m thrilled to lead Broken String as we bring this technology to more customers globally.”
Recent data presented at the Cell & Gene Meeting on the Mesa 2025, including work with the Innovative Genomics Institute at UC Berkeley, showcased how INDUCE-seq accelerates early-stage gene editing therapeutic development by cutting candidate screening timelines from months to days.
Health Technology Insights: Hammes Healthcare Appoints Justin Franklin as VP in Denver
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
Source- businesswire
